Drug interactions between bortezomib and cyclophosphamide
Interactions between your drugs
There were no interactions found in our database between bortezomib and cyclophosphamide - however, this does not necessarily mean no interactions exist. Always consult with your doctor or pharmacist.
- Bortezomib is in the drug class proteasome inhibitors.
- Bortezomib is used to treat the following conditions:
- Cyclophosphamide is a member of the drug class alkylating agents.
- Cyclophosphamide is used to treat the following conditions:
- Acute Lymphocytic Leukemia
- Acute Nonlymphocytic Leukemia
- Bladder Cancer
- Brain Tumor
- Breast Cancer
- Bullous Pemphigoid
- Cervical Cancer
- Chronic Lymphocytic Leukemia
- Chronic Myelogenous Leukemia
- Cogan's Syndrome
- Diffuse Large B-Cell Lymphoma
- Endometrial Cancer
- Ewing's Sarcoma
- Granulomatosis with Polyangiitis
- Hodgkin's Lymphoma
- IgA Nephropathy
- Mantle Cell Lymphoma
- Multiple Myeloma
- Multiple Sclerosis
- Mycosis Fungoides
- Nephrotic Syndrome
- Non-Hodgkin's Lymphoma
- Non-Small Cell Lung Cancer
- Organ Transplant, Rejection Prophylaxis
- Ovarian Cancer
- Prostate Cancer
- Rheumatoid Arthritis
- Small Cell Lung Cancer
- Systemic Lupus Erythematosus
- Systemic Sclerosis
- Testicular Cancer
- Wilms' Tumor
Drug and food interactions
No results found in our database - however, this does not necessarily mean no interactions exist. Always consult with your doctor or pharmacist.
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
|Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.|
|Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.|
|Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.|
|No information available.|
Do not stop taking any medications without consulting your healthcare provider.